World Sleep Industry ENCYCLOPEDIA

Ventilator Adherence Prediction Models

4.4.4

Scope, population, and prediction target

In a sleep-health context, a ventilator adherence prediction model primarily predicts use of prescribed positive-airway-pressure equipment, including continuous or auto-adjusting PAP, bilevel PAP for sleep-disordered breathing, and home noninvasive ventilation for selected patients. It should not classify invasive ventilation in critical care, ventilator weaning, or life-support decisions as “patient adherence.” Each device, disease, age group, and care setting requires a separate definition and validation.

A model must state when the prediction is made, for whom, for which future interval, and for what outcome—for example, need for early support before treatment, later use trajectory after the first few days, or a period at risk of interruption. A baseline model and a dynamic model using early device data are different tasks; the latter must not be advertised as a prediction available before treatment. Outputs should also separate duration, sleep-period coverage, pause or discontinuation, and likelihood of needing human contact.

“Adherence” is not a personality trait or a measure of obedience. Limited use can reflect poor interface fit, leak, pressure discomfort, nasal or oral symptoms, claustrophobia, insomnia, care burden, power loss, cost, network failure, hospitalization, travel, or a prescription that does not match current need. A legitimate model helps organize education, troubleshooting, and clinical review earlier. It must not label a person “noncompliant” or independently cancel treatment, equipment, or insurance rights.

Outcome definitions, thresholds, and clinical meaning

An outcome should define blower-on time, actual mask-on time where available, coverage of each sleep period, number of use nights, mean or median duration, consecutive interruption, and the denominator for the observation window. Sleep across midnight, daytime sleep, shift work, naps, split sessions, multiple devices, and travel need consistent rules. When cloud data are absent, no use must be distinguished from failed upload, account or serial-number mismatch, offline storage failure, and use of another device.

Common cutoffs based on fixed hours per night and a proportion of nights often come from administrative, research, or reimbursement rules rather than a universal physiological boundary for all people, outcomes, and regions. Binary labels place nearly identical people on opposite sides and can miss benefit below an administrative threshold or incomplete coverage despite meeting it. Continuous use, trajectory, and outcomes relevant to personal goals should be reported alongside any cutoff, with the rule version and jurisdiction retained.

Use is not the same as effectiveness or safety. Device-derived residual events, leak, pressure, or tidal-volume measures may use different algorithms and definitions across manufacturers, modes, and versions, while symptoms, sleep quality, daytime function, and appropriate clinical testing provide other evidence. A high predicted-use score does not establish a correct diagnosis, suitable settings, or controlled disease, and a low score does not quantify the net consequence of stopping treatment.

Inputs, data quality, and modifiable barriers

Pretreatment inputs may include diagnosis and prescription context, symptoms, comorbidities, prior device experience, interface selection and fitting, education, personal goals, language, and accessibility. After treatment starts, inputs may include daily use, start–stop patterns, leak and residual events, setting changes, humidification, faults, patient feedback, and support contacts. Every variable needs a timestamp, provenance, unit, and indication of whether care can modify it, so predictive association is not mislabeled as a cause.

Device telemetry should retain model, mode, firmware, time zone, sampling and aggregation method, transmission state, and data revisions. Blower operation does not always prove that the patient wore the mask, and an upload interruption does not prove that treatment stopped. Usage and event estimates may be distorted during extreme leak. Cross-manufacturer pooling requires a data dictionary and validated transformations; identically named “residual index” or “large leak” fields must not be assumed equivalent.

Reported experience and structural conditions matter as much as telemetry. Pain, skin injury, oral or nasal dryness, noise, anxiety, partner effects, housing, electricity, internet, cost, transport, shift work, caregiving, and speed of access to skilled help can alter use. Sensitive social data should be collected only for a defined purpose, lawful basis, and support pathway. Proxies such as postal code, insurance, or income must not lower service priority or turn resource deprivation into personal blame.

Temporal design, modeling, and external validation

Each prediction needs a frozen index time and only information available then. Minutes of use inside the outcome window, later calls, mask changes, pressure adjustments, and clinical actions cannot be backfilled as predictors. Feedback from an earlier alert that changed care must be recorded. Imputation, normalization, feature selection, and threshold tuning belong inside training folds, with separation by patient, household, clinical center, and time.

Reports should account for inclusion, exclusion, dropout, unfilled prescriptions, devices never connected, and loss to follow-up rather than train only on complete uploaders. Repeated patient-days or nights are not independent samples, so sample size cannot be expressed only as device-nights. Continuous outcomes, time to interruption, trajectory classes, and fixed-cutoff classification need appropriate methods. Death, hospitalization, device replacement, treatment switching, and equipment repossession are competing events, not simple nonadherence.

A frozen model needs external validation across diagnoses, devices and modes, sites, regions, payment systems, ages, sexes, race- and skin-related sensor differences, languages, disabilities, comorbidities, and stages of treatment. Evaluation should report calibration, error distributions, sensitivity, specificity, positive predictive value, coverage, lead time, and false-alert burden per patient, and compare with simple rules and current workflow. When current systematic evidence contains few heterogeneous studies without external validation, a high internal score is not a basis for deployment.

Interpretation, supportive intervention, and clinical safety

An output should state its target, horizon, uncertainty, and recent verifiable contributors, while making clear that feature importance is not causation. Low early use may indicate difficulty, but it may also reflect hospitalization, pending supplies, or missing transmission; the model must not infer motivation automatically. Explanations for staff should point to questions that can be checked, and language for patients should be neutral, understandable, correctable, and free from shaming rankings.

Prediction has value only when linked to timely, appropriate support. A pathway may include education, mask and interface assessment, care for skin or nasal and oral symptoms, humidification and fault troubleshooting, behavioral support, accessibility help, and review by qualified staff. Prospective trials should compare the model-guided pathway with existing care and assess use, symptoms, function, treatment effectiveness, patient experience, workload, cost, and harm. Finding risk is not itself an improvement.

A model must not automatically change pressure, mode, backup rate, oxygen flow, or other therapy settings, and a high use prediction cannot establish adequate ventilation. Marked breathing difficulty, chest pain, cyanosis, altered consciousness, severe sleepiness, suspected acute respiratory failure, or a critical device fault requires prompt professional or emergency action rather than waiting for an algorithm. Residual events, persistent symptoms, substantial leak, or inadequate noninvasive ventilation also require assessment in the prescription and clinical context.

Human workflow, autonomy, and equity

The workflow should specify who reviews an alert, when contact occurs, how device and patient status are confirmed, how actions are recorded, and how the loop is closed. A high-risk list must be prioritized by clinical urgency and available helpful action, not only by likelihood of limited use; people assigned low risk still need routine follow-up. Model abstention, stale data, device switching, or out-of-scope use should lead explicitly to human review rather than false certainty.

Patients should know which telemetry is collected, who can see it, and which decisions use the prediction, and should be able to access, explain, and correct records. Declining remote monitoring, lacking connectivity, or declining one recommendation must not automatically mean refusal of treatment. Shared decisions should respect comfort, goals, and alternatives. For children, people with cognitive disability, or those dependent on care, the roles and consent of patient, guardian, and caregiver should remain distinct.

Equity audits should identify who lacks a device, network, stable electricity, suitable mask, language service, transport, or timely clinic access and how those gaps affect labels, errors, and actions. Historical data from groups that received less support must not justify continuing to offer them less support. Alert rates, waiting times, intervention uptake, and outcomes should be reported across populations and resource settings. When credible performance cannot be established, automation should be limited and phone, offline, or face-to-face alternatives retained.

Privacy, regulation, and lifecycle governance

Usage telemetry can reveal sleep timing, presence at home or travel, treatment type, and health status, and becomes more sensitive when linked with clinical and social information. Governance should minimize data and separately define collection, transfer, retention, vendor access, cross-organization sharing, research, commercial use, and deletion. Employers, insurers, and equipment suppliers must not repurpose a prediction collected for treatment support into discipline, pricing, or automatic loss of coverage without a lawful and transparent process.

Systems need encryption, verification of device–account linkage, granular authorization, access logs, anomalous-upload detection, backup recovery, and incident response. Changes in models, firmware, cloud interfaces, data fields, care workflows, and payment policy can cause drift. Post-deployment monitoring should cover missingness, calibration, subgroup error, alert fatigue, overrides, and adverse events. Major changes should undergo shadow validation and staged release, with rollback and a manual fallback retained.

Regulatory and evidence obligations depend on actual claims, users, automation, and consequences of error. Developers should preserve intended and prohibited uses, outcome and cutoff versions, data lineage, model versions, validation, human-factors work, cybersecurity, and change records. The most credible model does not replace the patient or clinical team in judging who is “compliant.” It identifies solvable barriers earlier under transparent uncertainty and ensures that each alert can lead to safe, equitable, and optional help.